This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
J&J's Q4 Earnings Beat, Stock Down on Tepid 2025 Sales Guidance
by Zacks Equity Research
JNJ beats estimates for fourth-quarter earnings and sales. Its sales guidance for 2025 falls short of expectations.
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
by Ahan Chakraborty
Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney diseases as well certain brain ailments.
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Earnings?
by Zacks Equity Research
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. It remains to be seen if MedTech sales improved.
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer
by Zacks Equity Research
The FDA approves Amgen's Lumakras in combination with Vectibix for treating previously treated adults with KRAS G12C-mutated metastatic colorectal cancer.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Amgen (AMGN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $272.11, marking a +0.99% move from the previous day.
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
by Sundeep Ganoria
Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales growth of its tirzepatide products in Q4.
LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4
by Zacks Equity Research
LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates.
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Amgen (AMGN) closed at $267.10, indicating a -1.14% shift from the previous trading day.
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?
by Ekta Bagri
REGN's Eylea faces a rapid decline in sales, impacting overall performance even though Dupixent maintains momentum. We advise investors to stay on the sidelines for now.
LLY Falls Around 14% in 3 Months: How to Play the Stock
by Kinjel Shah
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Amgen (AMGN) closed at $262.05 in the latest trading session, marking a +1.34% move from the prior day.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The Zacks Analyst Blog Highlights Microsoft, Exxon Mobil, Amgen, PrimeEnergy Resources and FONAR
by Zacks Equity Research
Microsoft, Exxon Mobil, Amgen, PrimeEnergy Resources and FONAR are part of the Zacks top Analyst Blog.
Amgen (AMGN) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Amgen (AMGN) concluded the recent trading session at $258.59, signifying a -1.01% move from its prior day's close.
Top Analyst Reports for Microsoft, Exxon Mobil & Amgen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Exxon Mobil Corporation (XOM) and Amgen Inc. (AMGN), as well as two micro-cap stocks PrimeEnergy Resources Corporation (PNRG) and FONAR Corporation (FONR).
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Amgen (AMGN) closed at $260.64 in the latest trading session, marking a +0.52% move from the prior day.
Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Amgen (AMGN) closed at $259.30 in the latest trading session, marking a -1.28% move from the prior day.